Metformin in non-alcoholic steatohepatitis [6]

Lancet

Volumn 359, Issue 9303, 2002, Pages 355-356

  Urso, Rocco ^a   Visco Comandini, Ubaldo ^a  

^a NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; BIGUANIDE; GLICLAZIDE; METFORMIN; NUCLEOSIDE DERIVATIVE; PROTEINASE INHIBITOR;

ALCOHOLISM; AMINOTRANSFERASE BLOOD LEVEL; BODY FAT; DIET; DISEASE ASSOCIATION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG USE; DYSLIPIDEMIA; HEPATITIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLACTATEMIA; HYPOXIA; INSULIN RELEASE; INSULIN RESISTANCE; KIDNEY DISEASE; LACTATE BLOOD LEVEL; LACTIC ACIDOSIS; LETTER; LIPODYSTROPHY; LIVER FUNCTION; LIVER INJURY; LIVER METABOLISM; PATIENT MONITORING; PRIORITY JOURNAL; RISK FACTOR; SYNDROME X;

EID: 0037176572     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(02)07566-9     Document Type: Letter

References (5)

1. Metofrmin in non-alcoholic steatohepatitis
2. Effects of metformin on insulin resistance and central adiposity in patients receiving effective protease inhibitor therapy
3. Liver failure after long-term nucleoside antiretroviral therapy
4. Metformin-induced acute hepatitis
5. Contraindications to metformin therapy in patients with Type 2 diabetes: A population-based study of adherence to prescribing guidelines